Celltrion Healthcare, Stock Price Down 1.38% at This Time... Institutional Investors Net Buy 208,367 Shares in Last 5 Days

As of 9:30 AM on the 5th, Celltrion Healthcare is trading at 129,100 KRW, down 1.38% from the previous day. The trading volume is 335,177 shares, which is about 33.67% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of biosimilars developed by Celltrion.

On March 5th, researcher Kim Ji-ha from Meritz Securities stated, "The annual sales for 2021 are expected to reach 1.9448 trillion KRW (+19.5%), and operating profit is projected at 492.7 billion KRW (+36.1%). This year's growth drivers are the bio-better Remsima SC and the high-concentration Humira biosimilar Uplyma, scheduled for release in 2Q21E. Currently, Celltrion's COVID-19 treatment, Recilona, is under Rolling Review by the European EMA. As the company responsible for overseas sales of Recilona, significant performance growth is expected upon European approval and supply contract signing." He set the target price for Celltrion Healthcare at 145,000 KRW.

Over the past five days, individual investors have net sold 1,229 shares of Celltrion Healthcare, while foreigners and institutions have net sold 199,353 shares and net bought 208,367 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.